Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study

NCT07246330 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

340

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Toripalimab

Sponsor

Tianjin Medical University Cancer Institute and Hospital